RNA, U6 small nuclear 510, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-510P profile across patient tissues and cancer cell-line models. RNU6-510P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU6-510P is differentially expressed in 7, with the highest sampling consensus in KICH. Additionally, RNU6-510P RNA expression shows 17,945 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KICH, and THYM as cancer lineages where RNU6-510P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-510P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-510P survival associations across molecular data types. RNU6-510P RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-510P RNA expression–survival associations across cancer types. High RNU6-510P expression shows unfavorable associations in LIHC, MESO, LGG and CESC, but favorable associations in UCS and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU6-510P RNA expression.
This table summarizes RNU6-510P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-510P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-510P shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, CHOL, LUAD and HNSC. The KICH box plot shows higher RNU6-510P RNA expression in normal versus tumor tissue (log2 FC = −1.650, t-test p < 0.001).
This table shows molecular features associated with RNU6-510P in patient tissues and cancer cell lines. In patient samples, RNU6-510P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
